Goserelin Depot Versus Danazol in the Treatment of Endometriosis The Australian/New Zealand Experience*
article
OA: closed
CC0
⤵ 12 in-corpus citations
AI-generated summary
This randomized comparison found depot goserelin and danazol equally effective for endometriosis symptoms but noted significantly higher patient intolerance to danazol in the Australian/New Zealand population.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A multicentre, open, randomized comparison of depot goserelin versus danazol to treat endometriosis was undertaken in 9 Australian/New Zealand centres. The study compared the effects of the 2 drugs on subjective and objective parameters in women with symptomatic and/or infertility associated endometriosis. The duration of treatment was 24 weeks with either depot goserelin acetate, 3.6 mg, subcutaneously at 4-weekly intervals or danazol, 600 mg/day. As shown in previous studies, depot goserelin and danazol were equally effective in reducing endometriosis scores and pain. Patients in our study showed considerably more intolerance of study drugs, particularly danazol, than women in American and European reports: 19 of 36 women randomized to danazol in our study failed to complete 6 months therapy, because of adverse events (9/36) or because of unwillingness to continue with therapy (8/36). Consumer satisfaction with medical treatment for endometriosis was an important issue in this study.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (10)
- 9 Endometriosis: Medical therapy via openalex
- A Comparative Treatment Trial of Endometriosis Using the Gonadotrophin‐releasing Hormone Agonist, Nafarelin, and the Synthetic Steroid, Danazol via openalex
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis via openalex
- Impact of gestrinone on the course of asymptomatic endometriosis. via openalex
- “MEDICAL OOPHORECTOMY” USING A LONG-ACTING GNRH AGONIST-A POSSIBLE NEW APPROACH TO THE TREATMENT OF ENDOMETRIOSIS. via openalex
- Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up via openalex
- W2407038112 via openalex
- W2417044776 via openalex
- W2477008945 via openalex
Cited by (12)
- A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action 2024
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Ovulation suppression for endometriosis for women with subfertility 2007
- Management of the Pain Associated with Endometriosis: An Update of the Painful Problems 2006
- Advances in the management of endometriosis: an update for clinicians 2005
- An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis 2004
- Tratamiento de la endometriosis y medicina basada en la evidencia 2003
- The Treatment of Endometriosis 2002
- Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process 2002
- Treatment of Endometriosis 2001
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 1999
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:11:08.331550+00:00
License: CC0
· commercial use OK